Showing 20 of 223 recruiting trials for “acute-promyelocytic-leukemia”
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Allo HSCT Using RIC and PTCy for Hematological Diseases
👨⚕️ Mark Juckett, University of Minnesota Masonic Cancer Center📍 1 site📅 Started May 2023View details ↗
RecruitingNCT06334835 ↗
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
👨⚕️ Guillermo Garcia-Manero, MD, M.D. Anderson Cancer Center📍 7 sites📅 Started Apr 2023View details ↗
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
👨⚕️ Ryan D. Cassaday, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Mar 2023View details ↗
Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence
A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
👨⚕️ Linghui Xia, Professor, Department of Hematology, Wuhan Union Hospital, Tongji Medical college, Huazhong University of Science and Technology📍 1 site📅 Started Feb 2023View details ↗
Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies
👨⚕️ Nelson Hamerschlak, MD, PhH, Hospital Israelita Albert Einstein📍 1 site📅 Started Feb 2023View details ↗
BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL
Co-administration of CART22-65s and huCART19 for B-ALL
Pilot Imaging Study of Leukemia
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
👨⚕️ Janine Stutterheim, Dr, Princess Maxima Center for Pediatric Oncology in The Netherlands📍 112 sites📅 Started Dec 2022View details ↗
RecruitingNCT05929976 ↗
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →